The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization
Sign Up to like & getrecommendations! Published in 2020 at "European Radiology"
DOI: 10.1007/s00330-020-07078-z
Abstract: Objectives To identify clinical prognostic and predictive factors in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) undergoing sorafenib plus transarterial chemoembolization (TACE) and establish a prognostic score for these patients. Methods… read more here.
Keywords: pprd score; group; sorafenib plus; score ... See more keywords
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Gastroenterology"
DOI: 10.1007/s00535-017-1348-8
Abstract: BackgroundBiomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated… read more here.
Keywords: serum hmgb1; prognosis; treatment; hmgb1 concentrations ... See more keywords
Higher serum interleukin‐17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus‐associated advanced hepatocellular carcinoma treated with sorafenib
Sign Up to like & getrecommendations! Published in 2017 at "Cytokine"
DOI: 10.1016/j.cyto.2017.02.020
Abstract: Background Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable. The aim of the current study was to… read more here.
Keywords: progression; potential biomarker; treated sorafenib; serum ... See more keywords
Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of radiology"
DOI: 10.1016/j.ejrad.2017.10.017
Abstract: OBJECTIVES To investigate whether hepatic perfusion CT yields early imaging biomarkers predictive of the prognosis of hepatocellular carcinoma (HCC) patients treated with sorafenib. METHODS We evaluated 36 HCC patients who underwent hepatic perfusion CT before-… read more here.
Keywords: early imaging; imaging biomarkers; perfusion; survival rate ... See more keywords
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cancer"
DOI: 10.1186/s12885-017-3889-x
Abstract: BackgroundSorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical responses are rarely measurable during treatment.… read more here.
Keywords: survival benefits; treatment; cohort; patients advanced ... See more keywords
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0232449
Abstract: Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a… read more here.
Keywords: hepatocellular carcinoma; role; advanced hepatocellular; pni ... See more keywords
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2019 at "Internal Medicine"
DOI: 10.2169/internalmedicine.1594-18
Abstract: Objective The purpose of this multicenter retrospective study was to investigate the impact of the prognostic nutritional index (PNI) on the survival of Japanese patients with hepatocellular carcinoma (HCC) treated with sorafenib. Methods A total… read more here.
Keywords: multicenter retrospective; group; pni; retrospective study ... See more keywords
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Sign Up to like & getrecommendations! Published in 2022 at "Epigenomics"
DOI: 10.2217/epi-2021-0383
Abstract: Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating H3K27me3 and H3K36me3 in… read more here.
Keywords: carcinoma patients; h3k27me3 h3k36me3; hepatocellular carcinoma; treated sorafenib ... See more keywords
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.829483
Abstract: Introduction The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability… read more here.
Keywords: hepatocellular carcinoma; treated sorafenib; elderly patients; patients treated ... See more keywords
Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15102687
Abstract: Simple Summary Systemic therapy is current standard treatment for patients with hepatocellular carcinoma (HCC) with macrovascular invasion (MaVI). However, the outcome is poor. In the present study, we analyzed the outcome of patients treated with… read more here.
Keywords: treated sorafenib; survival; tace; therapy ... See more keywords